Table 1

Clinical features of patients with giant cell arteritis and Takayasu arteritis followed up at our Large-Vessel Vasculitis Clinic who completed the COVID-19 survey

Takayasu arteritis (n=67)Giant cell arteritis (n=95)
Demography
 Age, years (mean±SD)49±1373±12
 Female, n (%)58 (88)60 (63)
Comorbidities
 Smoking, n (%)8 (12)8 (8)
 Hypertension, n (%)38 (58)52 (55)
 Diabetes mellitus, n (%)4 (6)11 (12)
 Cardiovascular disease, n (%)11 (17)4 (4)
 Chronic kidney disease, n (%)1 (2)4 (4)
 Cancer, n (%)3 (5)4 (4)
Disease features
 Duration, months (mean±SD)142±10931±32
 Remission at last visit, n (%)59 (89)85 (90)
Glucocorticoids, n (%)44 (67%)57 (60%)
 Prednisolone dose, mg (mean±SD)5±75±7
csDMARDs, n (%)
 Methotrexate, n (%)34 (52)17 (18)
 Leflunomide, n (%)4 (6)1 (1)
 Mycophenolate Mofetil, n (%)5 (8)0
 Azathioprine, n (%)5 (8)0
 Sirolimus, n (%)3 (5)0
bDMARDs/tDMARDs, n (%)
 Tocilizumab, n (%)7 (11)46 (48)
 Infliximab, n (%)25 (38)
 Adalimumab, n (%)6 (9)
 Golimumab, n (%)2 (3)
 Tofacitinib, n (%)3 (5)
cs-/bDMARD combination, n (%)4 (4)4 (4)
  • bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.